Abstract 97P
Background
Myocarditis is a rare adverse effect of immune-checkpoint inhibitor therapy (ICI) associated with a high fatality rate and no clear predeterminants. European Society of Cardiology suggests baseline cardiac assessment and serial monitoring with ICI treatment. The volume of investigations recommended has been a barrier to adoption in practice.
Methods
We conducted a prospective study of clinical utility of baseline and serial cardiac assessment in a UK tertiary hospital. Patients were risk stratified by cardiac history, risk factors, baseline bloods including cardiac biomarkers and cardiac investigations, repeated at 3-4 weeks and 6-8 weeks. Aims; test feasibility; assess the value in risk stratifying patients to predict risk; determine if serial monitoring identified early cardiac toxicity.
Results
175 patients, 86 High risk, 89 Low risk. 8/175 patients baseline troponin >30. 28/175 patients baseline BNP >400. 2 patients had a troponin rise at 3-4 week, neither developed cardiotoxicity. 7 developed a troponin rise at 6-8 weeks, none developed cardiotoxicity. 32 patients had a BNP rise at 3-4 weeks. 9 significant. 1 patient BNP increased to >1000 without cardiotoxicity. 5 patients BNP approximately doubled; 2 patients rose >1000, 1 without cardiotoxicity, 1 who developed myocarditis later. 2 symptomatic patients with raised biomarkers and were treated for cardiotoxicity. 1 presented in SVT, LVEF 33%, CMR negative for myocarditis. 1 with syncopal episodes. In both cases biomarkers reduced on steroids, ICI was terminated.
Conclusions
All patients who developed cardiotoxicity were screened as high risk. 2 patients with cardiotoxicity were identified through clinical assessment not serial monitoring. Interpretation of cardiac biomarkers should accompany careful clinical assessment and liaison with cardiology. Baseline assessment supports decision making. Risk stratification may be a way to streamline monitoring.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
53P - Novel ex-vivo manufacturing of transiently expressed armoured CAR T cells for glioblastoma
Presenter: Saket Srivastava
Session: Poster Display session
Resources:
Abstract
54P - Superior antitumor activities of fourth-generation CAR-T cells containing three costimulatory domains targeting GD2-positive tumors
Presenter: Jatuporn Sujjitjoon
Session: Poster Display session
Resources:
Abstract
55P - Engineering of chimeric cytokine receptors (CCR) to induce IL-7 signaling to CAR-T cells for solid tumor treatment
Presenter: Marta Soria Castellano
Session: Poster Display session
Resources:
Abstract
56P - Potent antitumor efficiency of CD19-CAR T cells self-secreting PD-L1 x CD3 BiTE against aggressive B-cell lymphoma
Presenter: Jatuporn Sujjitjoon
Session: Poster Display session
Resources:
Abstract
57P - SENDER™ Directed LNP Delivery of mRNA for In Situ generation of highly potent CAR T Cells
Presenter: Biao Ma
Session: Poster Display session
Resources:
Abstract
58P - Cardiovascular outcomes of novel CAR-T cell therapies: A meta-analysis of incidence, risk factors, and management of cardiotoxicity
Presenter: Hashim Talib Hashim
Session: Poster Display session
Resources:
Abstract
59P - Long term survival data from all recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients treated with MVX-ONCO-1 during open-labelled phase I and phase IIa clinical trials
Presenter: Nicolas Mach
Session: Poster Display session
Resources:
Abstract
60P - Innovative applications of neoantigens in dendritic cell-derived exosome (DEX) therapy and their impact on personalized cancer treatment
Presenter: Ramon Gutierrez
Session: Poster Display session
Resources:
Abstract
61P - Optimized protocol for the accelerated production of dendritic cell-derived exosomes (DEXs): Achieving speed without compromising efficacy
Presenter: Ramon Gutierrez
Session: Poster Display session
Resources:
Abstract
62P - Ecto-CRT induction of NKp46 surface expression increases osimertinib-resistant lung cancer’s sensitivity to NK cells
Presenter: Sumei Chen
Session: Poster Display session
Resources:
Abstract